Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) tinted gains of +0.92% (+0.03 points) to US$3.29. The volume of 0.16 Million shares climbed down over an trading activity of 466.03 Million shares. EPS ratio determined by looking at last 12 month figures is -2.47. Over the same time span, the stock marked US$10.26 as its best level and the lowest price reached was US$2.74. The corporation has a market cap of US$147.49 Million.
Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM)’s earnings per share has been growing at a -18.2 percent rate over the past 5 year when average revenue increase was noted as -33.9 percent. The return on equity ratio or ROE stands at 0 percent while most common profitability ratio return on investment (ROI) was -74.5 percent. The company’s institutional ownership is monitored at 58.6 percent. The company’s net profit margin has achieved the current level of 0 percent and possesses 54.8 percent gross margin.
Daily Analyst Recommendations
A number of key analysts, polled by FactSet, shared their views about the current stock momentum. The forecast of 4 surveyed investment analysts covering the stock advises investors to Buy stake in the company. At present, 0 analysts call it Sell, while 0 think it is Hold. Recently, analysts have updated the overall rating to 1.33. 2 analysts recommended Overweight these shares while 0 recommended Underweight, according to FactSet data.
J. Alexander’s Holdings, Inc. (NYSE:JAX) is worth US$137.51 Million and has recently risen 3.26% to US$9.49. The latest exchange of 0.05 Million shares is below its average trading activity of 62.19 Million shares. The day began at US$9.22 but the price moved to US$9.06 at one point during the trading and finally capitulating to a session high of US$9.49. The stock tapped a 52-week high of US$13.4 while the mean 12-month price target for the shares is US$15.
Currently, the stock carries a price to earnings ratio of 18.72, a price to book ratio of 1.24, and a price to sales ratio of 0.57. For the past 5 years, the company’s revenue has grown 8.3%, while the company’s earnings per share has grown 15.5%. With an institutional ownership near 89.6%, it carries an earnings per share ratio of 0.51.
Inside Look At Analysts Reviews
Latest analyst recommendations could offer little help to investors. The stock is a Buy among 1 brokerage firms polled by Factset Research. At present, 0 analysts recommended Holding these shares while 0 recommended sell, according to FactSet data. 0 analysts call it Underweight, while 0 think it is Overweight. Recently, investment analysts covering the stock have updated the mean rating to 1.